Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers Journal Article

Authors: Jäger, E.; Gnjatic, S.; Nagata, Y.; Stockert, E.; Jäger, D.; Karbach, J.; Neumann, A.; Rieckenberg, J.; Chen, Y. T.; Ritter, G.; Hoffman, E.; Arand, M.; Old, L. J.; Knuth, A.
Article Title: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
Abstract: Cancer-testis antigen NY-ESO-1 is one of the most immunogenic tumor antigens defined to date. Spontaneous humoral and CD8+ T-cell responses to NY-ESO-1 are detected in 40-50% of patients with advanced NY-ESO-1-expressing tumors. A clinical trial was initiated to study the immunological effects of intradermal vaccination with 3 HLA-A2-binding NY-ESO-1 peptides in 12 patients with metastatic NY-ESO-1-expressing cancers. Seven patients were NY-ESO-1 serum antibody negative, and five patients were NY-ESO-1 serum antibody positive at the outset of the study. Primary peptide-specific CD8+ T-cell reactions and delayed-type hypersensitivity responses were generated in four of seven NY-ESO-1 antibody-negative patients. Induction of a specific CD8+ T-cell response to NY-ESO-1 in immunized antibody-negative patients was associated with disease stabilization and objective regression of single metastases. NY-ESO-1 antibody-positive patients did not develop significant changes in baseline NY-ESO-1-specific T-cell reactivity. However, stabilization of disease and regression of individual metastases were observed in three of five immunized patients. These results demonstrate that primary NY-ESO-1-specific CD8+ T-cell responses can be induced by intradermal immunization with NY-ESO-1 peptides, and that immunization with NY-ESO-1 may have the potential to alter the natural course of NY-ESO-1-expressing tumors.
Keywords: clinical article; cd8 antigen; t lymphocyte; cd8-positive t-lymphocytes; proteins; metastasis; granulocyte macrophage colony stimulating factor; membrane proteins; cytotoxicity; cytokine; amino acid sequence; antigens, neoplasm; cancer vaccine; cancer vaccines; vaccination; tumor cell; peptides; cytotoxicity, immunologic; cd4 antigen; antibodies, neoplasm; testis; interleukin 12; immunization; delayed hypersensitivity; cancer immunology; hypersensitivity, delayed; humans; human; male; priority journal; article
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Volume: 97
Issue: 22
ISSN: 0027-8424
Publisher: National Academy of Sciences  
Date Published: 2000-10-24
Start Page: 12198
End Page: 12203
Language: English
DOI: 10.1073/pnas.220413497
PUBMED: 11027314
PROVIDER: scopus
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Yasuhiro Nagata
    11 Nagata
  2. Sacha Gnjatic
    111 Gnjatic
  3. Gerd Ritter
    158 Ritter
  4. Lloyd J Old
    386 Old